Tokai Pharmaceuticals (TKAI) Receives ‘Analyst’ Rating

Tokai Pharmaceuticals (TKAI) : Zacks Investment Research ranks Tokai Pharmaceuticals (TKAI) as 3, which is a Hold recommendation. Not everyone is convinced about the stocks future, hence, the stock receives 1 Sell recommendation. A total of 5 analysts believe that the stock has a limited upside, hence they advise a Hold. The average broker rating of 6 research analysts is 3.17, which indicates as a Hold.

Tokai Pharmaceuticals (TKAI) : The most positive equity analysts on Tokai Pharmaceuticals (TKAI) expects the shares to touch $2, whereas, the least positive believes that the stock will trade at $1 in the short term. The company is covered by 4 Wall Street Brokerage Firms. The average price target for shares are $1.68 with an expected fluctuation of $0.47 from the mean.


Also, Bank of America downgrades their rating on the shares of Tokai Pharmaceuticals (NASDAQ:TKAI). The current rating of the shares is Underperform. Earlier, the shares were rated a Neutral by the brokerage firm. The rating by the firm was issued on July 28, 2016.

Tokai Pharmaceuticals (NASDAQ:TKAI): After opening at $1.04, the stock dipped to an intraday low of $1.02 on Thursday. However, the bulls stepped in to buy at lower levels and pushed the stock higher. The stock touched an intraday high of $1.4 and the buying power remained strong till the end. The stock closed at $1.28 for the day, a gain of 25.49% for the day session. The total traded volume was 8,773,113. The stocks close on the previous trading day was $1.02.

Tokai Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company. The Company is focused on developing therapies for the treatment of prostate cancer and other hormonally-driven diseases. The Companys lead drug candidate galeterone is a multi-targeted, oral small molecule drug candidate that has advantages over existing prostate cancer therapies. The Company is focusing its initial development of galeterone on the treatment of patients with castration resistant prostate cancer (CRPC), whose prostate tumor cells express an altered androgen receptor that is truncated. Galeterone acts by disrupting the androgen receptor signaling pathway, which is the primary pathway that drives prostate cancer growth. The Company is conducting a Phase II clinical trial of galeterone, known as ARMOR2 trial, for the treatment of multiple CRPC populations.

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.